ACRV vs. CNTA, ARCT, SPRY, ARQT, PRTC, COGT, ETNB, STOK, NRIX, and OCUL
Should you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Centessa Pharmaceuticals (CNTA), Arcturus Therapeutics (ARCT), ARS Pharmaceuticals (SPRY), Arcutis Biotherapeutics (ARQT), PureTech Health (PRTC), Cogent Biosciences (COGT), 89bio (ETNB), Stoke Therapeutics (STOK), Nurix Therapeutics (NRIX), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical preparations" industry.
Acrivon Therapeutics (NASDAQ:ACRV) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, community ranking, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.
Acrivon Therapeutics has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Comparatively, Centessa Pharmaceuticals has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500.
71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 8.5% of Acrivon Therapeutics shares are owned by insiders. Comparatively, 11.6% of Centessa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Acrivon Therapeutics received 5 more outperform votes than Centessa Pharmaceuticals when rated by MarketBeat users. Likewise, 96.15% of users gave Acrivon Therapeutics an outperform vote while only 48.78% of users gave Centessa Pharmaceuticals an outperform vote.
Acrivon Therapeutics has higher earnings, but lower revenue than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Centessa Pharmaceuticals had 1 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 2 mentions for Centessa Pharmaceuticals and 1 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 1.17 beat Centessa Pharmaceuticals' score of 0.51 indicating that Acrivon Therapeutics is being referred to more favorably in the media.
Acrivon Therapeutics presently has a consensus target price of $22.57, indicating a potential upside of 211.33%. Centessa Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 13.64%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Acrivon Therapeutics is more favorable than Centessa Pharmaceuticals.
Acrivon Therapeutics' return on equity of -49.65% beat Centessa Pharmaceuticals' return on equity.
Summary
Acrivon Therapeutics beats Centessa Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Acrivon Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acrivon Therapeutics Competitors List
Related Companies and Tools
